Setidegrasib, a targeted therapy targeting KRAS G12D protein, shows promising early results in shrinking advanced lung and pancreatic cancers.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Experimental KRAS G12D drug slows cancer growth, shrinks tumors in early test
Setidegrasib Drug name
KRAS G12D Target protein
Advanced Lung And Pancreatic Cancer types treated
First-In-Human Trial stage